Schizophrenia drug comparison finds differences in symptoms and selected side effects
A pooled trial analysis favored high-dose olanzapine for negative symptom scores, while several other measures showed no statistically significant difference from clozapine.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
High-dose olanzapine performed better on a scale measuring negative symptoms, but overall clinical impression and positive symptom scores did not differ significantly from clozapine. Excess salivation and blood pressure drops on standing were reported more often with clozapine. This pattern does not establish that the drugs are equivalent or that olanzapine is safer overall.
This abstract-based comparison does not report effect sizes, exact doses, or detailed adverse-event rates. Follow-up was limited, so it cannot settle longer-term safety or the practical size of the symptom difference.
What researchers found
PANSS negative symptom scores
Favored high-dose olanzapine over clozapine across trials with 14–24 weeks of follow-up; effect size not reported.
Reading outcomes separately
The researchers pooled randomized drug comparisons in treatment-resistant schizophrenia. They assessed clinical impressions, Positive and Negative Syndrome Scale (PANSS) scores, and selected adverse events, so results need to be read outcome by outcome.
What remained uncertain
Weight gain was reported at a similar frequency with both drugs. This describes its incidence; the abstract does not compare amounts gained. Similarity and nonsignificant findings on other scales do not establish equivalent effects.
The original publication
High-dose Olanzapine Versus Clozapine in Treatment-resistant Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Kotochinsky M, Eloa Oliveira Fonseca P, Mora L et al.
J Psychiatr Pract · 2026
- PubMed ID
- 41894186
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.